

# Expert Recommendations for Reporting CLDN18.2 by IHC in Gastric/GOJ Cancer

Developed collaboratively by the CLDN18.2 Expert Committee, the following template can help you generate and integrate CLDN18.2 reporting into your current protocols.

## Scoring algorithm

Percentage of tumour cells demonstrating moderate-to-strong (2+/3+) membranous CLDN18-specific staining.

### Percentage of tumour cells with membranous staining

Tumour cells with moderate staining (2+): \_\_\_\_\_ %

Tumour cells with strong staining (3+): \_\_\_\_\_ %

Total tumour cells with moderate-to-strong (2+/3+) staining: \_\_\_\_\_ %  
(Sum of 2 lines above)

### CLDN18.2 testing method (Protein expression by immunohistochemistry)

(Select one)

☐ TGA approved test

\_\_\_\_\_  
(Specify test/vendor)

☐ Laboratory-developed test

\_\_\_\_\_  
(Specify name of clone)

## Notes

The CLDN18.2 Expert Committee is comprised of some of the world's leading pathologists, including Matteo Fassan, MD, PhD, Takeshi Kuwata, MD, PhD, Kristina A. Matkowskyj, MD, PhD, Christoph Röcken, MD, and Josef H. Rüschhoff, MD. The members of the committee have been contracted as paid advisors through Astellas Pharma Inc. and have received compensation for their time.

G/GOJ = gastric/gastro-oesophageal

IHC = Immunohistochemistry

Astellas Pharma Australia Pty Ltd. ABN 81 147 915 482. Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.

All trademarks are the property of their respective owners.

MAT-AU-NON-2025-00007 March 2025

# Expert Recommendations for Reporting CLDN18.2 by IHC in Gastric/GOJ Cancer

Developed collaboratively by the CLDN18.2 Expert Committee, the following template can help you generate and integrate CLDN18.2 reporting into your current protocols.

## Scoring algorithm

Percentage of tumour cells demonstrating moderate-to-strong (2+/3+) membranous CLDN18-specific staining.

### Percentage of tumour cells with membranous staining

Tumour cells with moderate staining (2+): \_\_\_\_\_ %

Tumour cells with strong staining (3+): \_\_\_\_\_ %

Total tumour cells with moderate-to-strong (2+/3+) staining: \_\_\_\_\_ %  
(Sum of 2 lines above)

### CLDN18.2 status

(Select one)

☐ Inconclusive

☐ Positive  
(≥75% tumour staining)

☐ Negative  
(<75% tumour staining)

### CLDN18.2 testing method (Protein expression by immunohistochemistry)

(Select one)

☐ TGA approved test

\_\_\_\_\_  
(Specify test/vendor)

☐ Laboratory-developed test

\_\_\_\_\_  
(Specify name of clone)

## Notes

The CLDN18.2 Expert Committee is comprised of some of the world's leading pathologists, including Matteo Fassan, MD, PhD, Takeshi Kuwata, MD, PhD, Kristina A. Matkowskyj, MD, PhD, Christoph Röcken, MD, and Josef H. Rüschhoff, MD. The members of the committee have been contracted as paid advisors through Astellas Pharma Inc. and have received compensation for their time.

G/GOJ = gastric/gastro-oesophageal

IHC = Immunohistochemistry

Astellas Pharma Australia Pty Ltd. ABN 81 147 915 482. Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.

All trademarks are the property of their respective owners.

MAT-AU-NON-2025-00007 March 2025

